COMPANY

Frontier Medicines Corporation

HQ: South San Francisco, CA source · frontiermeds.com ↗

4 open jobs · last seen Oct 23, 2026 · 1 source

Location: South San Francisco, CA · source · Jul 12, 2021

Profile checked Oct 10, 2026

Keywords: Advanced Solid Tumors With KRAS G12C Mutations Non Small Cell Lung Cancer Colorectal Cancer KRAS G12C Pancreatic Cancer FMC-376

4Open jobs 1Trials (company is sponsor)

Hiring

Title	Location (from posting)	Employer posted	First seen
Director/Sr. Director, Quality Assurance (GCP/GMP)	Boston, Massachusetts, United States	Oct 22, 2026	Oct 23, 2026
VP, Clinical Pharmacology	Boston, Massachusetts, United States	Oct 22, 2026	Oct 23, 2026
Sr. Clinical Trial Manager	Boston, Massachusetts, United States	Sep 14, 2026	Oct 16, 2026
AI Cheminformatics Engineer I	South San Francisco, California, United States	Jun 25, 2026	Oct 16, 2026

See all 4 jobs

Raises and deals from press releases

Raise Series C · $20M · announced Aug 27, 2025 Company release ↗
Source quote
- Aug 27, 2025 · Company release ↗
  “Frontier Medicines Appoints Gerardo Ubaghs as Chief Financial Officer and Announces $20 Million Series C Extension -Gerardo Ubaghs brings high-profile global biopharma strategic and capital markets experience as newly appointed Chief Financial Officer (CFO) -Company adds $20 million to close”
Raise Series C · $80M · announced Feb 22, 2024 Company release ↗
Source quote
- Feb 22, 2024 · Company release ↗
  “Frontier Medicines Announces Oversubscribed $80 Million Series C”

Raises announced in these releases: $100M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Timeline

Aug 27, 2025 Raise Series C · $20M source ↗
Feb 22, 2024 Raise Series C · $80M source ↗
Feb 12, 2024 Trial start Phase 1/Phase 2: A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors source ↗

Upcoming milestones

2027-10 (ESTIMATED) · Phase 1/Phase 2 · A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors · NCT06244771

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 1

Record	Title	Phase	Status	Start	Primary completion
NCT06244771	A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors	Phase 1/Phase 2	Recruiting	Feb 12, 2024	2027-10 (estimated)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

InvestorListed in the portfolio of MPM BioImpact (captured Oct 12, 2026). portfolio page ↗

Open jobs 4

Title	Location (from posting, not HQ)	Employer posted	First seen	Level
Director/Sr. Director, Quality Assurance (GCP/GMP)	Boston, Massachusetts, United States	Oct 22, 2026	Oct 23, 2026	Not stated
VP, Clinical Pharmacology	Boston, Massachusetts, United States	Oct 22, 2026	Oct 23, 2026	Not stated
Sr. Clinical Trial Manager	Boston, Massachusetts, United States	Sep 14, 2026	Oct 16, 2026	Senior
AI Cheminformatics Engineer I	South San Francisco, California, United States	Jun 25, 2026	Oct 16, 2026	Entry

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

Connect

See your connections at Frontier Medicines on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-18

Careers page (Oct 8, 2026)